APA (7th ed.) Citation

Hubbeling, H., Leithner, D., Silverman, E., Flynn, J., Devlin, S., Shah, G., . . . Imber, B. (2024). Improvement in Radiomic Features Following Bridging Therapy is Prognostic for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcome. International Journal of Radiation Oncology, Biology, Physics, 120(2), S66. https://doi.org/10.1016/j.ijrobp.2024.07.111

Chicago Style (17th ed.) Citation

Hubbeling, H.G, et al. "Improvement in Radiomic Features Following Bridging Therapy Is Prognostic for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcome." International Journal of Radiation Oncology, Biology, Physics 120, no. 2 (2024): S66. https://doi.org/10.1016/j.ijrobp.2024.07.111.

MLA (9th ed.) Citation

Hubbeling, H.G, et al. "Improvement in Radiomic Features Following Bridging Therapy Is Prognostic for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcome." International Journal of Radiation Oncology, Biology, Physics, vol. 120, no. 2, 2024, p. S66, https://doi.org/10.1016/j.ijrobp.2024.07.111.